Greenwich Lifesciences Inc (GLSI)

$24.10 -1.78 (-6.88%)
Market Cap 333.91M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 141,900
Avg Vol 402,764
Day's Range N/A - N/A
Shares Out 13.86M
Stochastic %K 4%
Beta 1.50
Analysts Strong Sell
Price Target $47.50

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States and Romania. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company also develops FLAMINGO-01, which is in Phase III clinical trial designed to evaluate the safety and efficacy...

Industry: Biotechnology
Sector: Healthcare
Phone: 832 819 3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
Toontje1
Toontje1 Mar. 22 at 12:37 AM
$GLSI Trying to calculate when 14 events will be reached. Help me out! Is this correct ? 15% per year on average seeems way to high. Normal 4% per year. Anyone ? Chat told me this: Average HER2+ patients after standard treatment (trastuzumab + chemotherapy): • Stage II–III: 2–5 year follow-up: approximately 10–20% total recurrence • This is cumulative, not per year High-risk patients (such as those selected by Greenwich): • Larger tumor stage • Aggressive subtype • Possibly previously treated or with metastases • Recurrence rate can be 30–40% cumulative over 2–3 years, or roughly 15% per year on average
2 · Reply
doc123266
doc123266 Mar. 21 at 10:49 PM
$GLSI
0 · Reply
doc123266
doc123266 Mar. 21 at 10:47 PM
$GLSI two of these are facilities have been or are currently participating in glsi-100 p2 or p3 trial. MDA in p2 and now GR in p3
0 · Reply
History101
History101 Mar. 21 at 1:52 AM
$SLS if SLS manages this ATM as expertly as $GLSI has done with theirs, then this ATM is indeed an asset for SLS and will allow more meaningful upward share price movement. Bullish imo. GLTALs!!
1 · Reply
Daryl1689
Daryl1689 Mar. 20 at 9:44 PM
Two companies, two peptide cancer treatments. $SLS and $GLSI , one company spends money like its free and the other pinches every single penny.
4 · Reply
alandjoyce
alandjoyce Mar. 20 at 7:26 PM
$GLSI It'll be back. Just some panicking or taking from here to cover thier Asses elsewhere.
0 · Reply
insidersruleloosersdrool
insidersruleloosersdrool Mar. 20 at 6:37 PM
$GLSI I promised myself I would not buy any more GLSI.I have a 200 bid at $24.16 waiting for someone to give me shares. Volume of less than 70k, and down 6% is crazy. I still have more dollars and will buy more if it falls further. And to think it hit $30.00 this week. Plain nuts.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 20 at 3:52 PM
$GLSI this is the add zone. It's Friday I will take 150 shares at $24.90
0 · Reply
alandjoyce
alandjoyce Mar. 20 at 3:44 PM
$GLSI Have a great weekend. Will miss miss you Chuck, Rip🙏
0 · Reply
grandefappuccino
grandefappuccino Mar. 20 at 3:30 PM
$GLSI sorry guys I know this has been asked a billion times.. When are we speculating the IA data drop?
1 · Reply
Latest News on GLSI
Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Mar 19, 2026, 6:00 AM EDT - 2 days ago

Greenwich LifeSciences Announces Addition of City of Hope to FLAMINGO-01

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Mar 18, 2026, 6:00 AM EDT - 3 days ago

Greenwich LifeSciences Provides Update on Upcoming AACR Meeting

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Mar 17, 2026, 6:00 AM EDT - 4 days ago

Greenwich LifeSciences Provides Update Showing Continued Reduction in Recurrence Rate in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Mar 16, 2026, 6:00 AM EDT - 5 days ago

Greenwich LifeSciences Announces Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Mar 3, 2026, 6:00 AM EST - 18 days ago

Greenwich LifeSciences Provides Update on Increased Patient Screen Rate in FLAMINGO-01

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Feb 24, 2026, 6:00 AM EST - 25 days ago

Greenwich LifeSciences Announces Acceptance of Two Abstracts at AACR Annual Meeting 2026

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Jan 27, 2026, 6:00 AM EST - 7 weeks ago

Greenwich LifeSciences Provides Update on FLAMINGO-01 Cash Burn Rate and Financing Strategy

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Jan 22, 2026, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Dec 29, 2025, 6:00 AM EST - 2 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to September 30, 2026

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Dec 22, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy

Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Dec 15, 2025, 11:11 AM EST - 3 months ago

Why Is Greenwich LifeSciences Stock Surging After Data From Breast Cancer Vaccine?

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Dec 15, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Announces Preliminary Analysis Showing 80% Recurrence Rate Reduction in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Dec 8, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Announces Completion of Enrollment in the Open Label Arm of FLAMINGO-01

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Dec 3, 2025, 6:00 AM EST - 3 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01, Screening Over 1,000 Patients to Date

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Oct 9, 2025, 6:00 AM EDT - 5 months ago

Greenwich LifeSciences Announces Addition of Austria to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Oct 2, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Sep 30, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Sep 18, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Sep 10, 2025, 6:00 AM EDT - 6 months ago

Greenwich LifeSciences' GLSI-100 Granted US FDA Fast Track Designation

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Aug 20, 2025, 9:25 AM EDT - 7 months ago

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Aug 19, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Aug 13, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Aug 11, 2025, 6:00 AM EDT - 7 months ago

Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 1 year ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 2 years ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 3 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Toontje1
Toontje1 Mar. 22 at 12:37 AM
$GLSI Trying to calculate when 14 events will be reached. Help me out! Is this correct ? 15% per year on average seeems way to high. Normal 4% per year. Anyone ? Chat told me this: Average HER2+ patients after standard treatment (trastuzumab + chemotherapy): • Stage II–III: 2–5 year follow-up: approximately 10–20% total recurrence • This is cumulative, not per year High-risk patients (such as those selected by Greenwich): • Larger tumor stage • Aggressive subtype • Possibly previously treated or with metastases • Recurrence rate can be 30–40% cumulative over 2–3 years, or roughly 15% per year on average
2 · Reply
doc123266
doc123266 Mar. 21 at 10:49 PM
$GLSI
0 · Reply
doc123266
doc123266 Mar. 21 at 10:47 PM
$GLSI two of these are facilities have been or are currently participating in glsi-100 p2 or p3 trial. MDA in p2 and now GR in p3
0 · Reply
History101
History101 Mar. 21 at 1:52 AM
$SLS if SLS manages this ATM as expertly as $GLSI has done with theirs, then this ATM is indeed an asset for SLS and will allow more meaningful upward share price movement. Bullish imo. GLTALs!!
1 · Reply
Daryl1689
Daryl1689 Mar. 20 at 9:44 PM
Two companies, two peptide cancer treatments. $SLS and $GLSI , one company spends money like its free and the other pinches every single penny.
4 · Reply
alandjoyce
alandjoyce Mar. 20 at 7:26 PM
$GLSI It'll be back. Just some panicking or taking from here to cover thier Asses elsewhere.
0 · Reply
insidersruleloosersdrool
insidersruleloosersdrool Mar. 20 at 6:37 PM
$GLSI I promised myself I would not buy any more GLSI.I have a 200 bid at $24.16 waiting for someone to give me shares. Volume of less than 70k, and down 6% is crazy. I still have more dollars and will buy more if it falls further. And to think it hit $30.00 this week. Plain nuts.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Mar. 20 at 3:52 PM
$GLSI this is the add zone. It's Friday I will take 150 shares at $24.90
0 · Reply
alandjoyce
alandjoyce Mar. 20 at 3:44 PM
$GLSI Have a great weekend. Will miss miss you Chuck, Rip🙏
0 · Reply
grandefappuccino
grandefappuccino Mar. 20 at 3:30 PM
$GLSI sorry guys I know this has been asked a billion times.. When are we speculating the IA data drop?
1 · Reply
Toontje1
Toontje1 Mar. 20 at 3:11 PM
$GLSI 25 looks bottom, next week will be fun
0 · Reply
TheinvestmetABCD
TheinvestmetABCD Mar. 20 at 2:31 PM
$GLSI In my opinion SP500 has almost reached a temporary bottom and we could move higher from these levels next 1-2 weeks. Hopefully we gather enough momentum to break the 30s for good! Time and data are both on our side :)
0 · Reply
yft212
yft212 Mar. 20 at 2:14 PM
$GLSI Nothing wrong with a little consolidation. Have a nice weekend!
0 · Reply
Lets_Go_Brndn
Lets_Go_Brndn Mar. 20 at 12:45 PM
$GLSI Price doesn’t matter when the release 14 event data. The lower it is the higher the percent of climb. Just add whenever you can. Loaning the shares out provides some rope for the shorts and yourself some nice income. Doesn’t hurt us ether. I couldn’t care less if anyone disagrees. Won’t matter as the more the shorts the higher & faster we will go up.
2 · Reply
Younotakemycandle
Younotakemycandle Mar. 20 at 8:13 AM
$GLSI Good Morning from Yorkshire, England. Hope you all have a great day!
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 20 at 1:33 AM
$GLSI RSI: 44.44, MACD: 0.3986 Vol: 1.77, MA20: 26.32, MA50: 26.71 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Waterwing
Waterwing Mar. 19 at 10:53 PM
$GLSI
0 · Reply
Jack_Danielss
Jack_Danielss Mar. 19 at 8:06 PM
$GLSI should be, technicals have reset beautifully, should attack the $30 in short order
0 · Reply
KINGSTOCKERS
KINGSTOCKERS Mar. 19 at 7:33 PM
$GLSI If bottom was $25 it’s go time from here
0 · Reply
FastRocketTraders
FastRocketTraders Mar. 19 at 7:06 PM
If you're in the market to get in to them runners early before the big moves... @ElevenXProfits is a good bull FOLLOW - I made cash on many of his calls. 💎 Still holding $ECOX $NUAI $AMFN $GLSI
1 · Reply
TrailBoss
TrailBoss Mar. 19 at 6:48 PM
$GLSI
0 · Reply
GDonovan_
GDonovan_ Mar. 19 at 6:33 PM
$GLSI biotech setup with squeeze risk and the upside gets real only if volume expands hard
0 · Reply